Physician profile
Ayman Daoud
NPI 1073640355
$3,357.02
in general payments reported to CMS, 2019-2025
31 companies · $693 in 2025
The $693 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $602 · 2020: $275 · 2021: $363 · 2022: $445 · 2023: $484 · 2024: $495 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,671.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $348.58 | 2021-2025 | Ubrelvy, Qulipta |
| Pfizer INC. | $336.45 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $326.35 | 2019-2024 | Nuplazid |
| Lilly USA, LLC | $325.20 | 2020-2025 | Mounjaro, Kisunla, Zepbound |
| Daiichi Sankyo INC. | $230.00 | 2019 | |
| Glaxosmithkline, LLC. | $224.33 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Axsome Therapeutics, INC. | $204.23 | 2025 | Auvelity |
| Astrazeneca Pharmaceuticals Lp | $160.73 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Sunovion Pharmaceuticals INC. | $153.00 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $130.00 | 2023 | Libtayo |
| Novartis Pharmaceuticals Corporation | $123.12 | 2019-2024 | |
| Mylan Specialty L.P. | $105.73 | 2024 | Yupelri |
| Janssen Pharmaceuticals, INC | $91.29 | 2019-2021 | |
| Emd Serono, INC. | $87.17 | 2019 | |
| Supernus Pharmaceuticals, INC. | $64.08 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $51.86 | 2019-2022 | |
| Medtronic Vascular, INC. | $47.71 | 2019-2020 | |
| Viatris Specialty LLC | $42.87 | 2025 | Yupelri |
| Exact Sciences Corporation | $37.36 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $36.96 | 2019-2020 | |
| Allergan, INC. | $30.48 | 2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $29.56 | 2022 | |
| Almatica Pharma LLC | $29.24 | 2020 | |
| Biogen, INC. | $24.44 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $18.97 | 2021 | |
| Electromed, INC. | $18.11 | 2025 | Smartvest |
| Indivior INC. | $17.23 | 2024 | Sublocade |
| Celgene Corporation | $17.10 | 2022 | |
| Portola Pharmaceuticals, LLC | $17.06 | 2019 | |
| Grifols USA, LLC | $14.84 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayman Daoud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.